Thermo Fisher Scientific Inc. received expanded emergency use authorization (EUA) from the FDA for its multiplex real-time PCR test for the qualitative detection of nucleic acid from SARS‑CoV‑2, the virus that causes COVID-19. Thermo Fisher’s Applied Biosystems TaqPath COVID-19 Combo Kit, initially granted EUA on March 13 and subsequently expanded on April 20, is designed to deliver test results within four hours of a sample being received and processed by a CLIA high-complexity lab. Th...